The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Keld, Richard ^a   Guo, Baoqiang ^a   Downey, Paul ^b   Gulmann, Christian ^b   Ang, Yeng S ^a   Sharrocks, Andrew D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR PEA3; UNCLASSIFIED DRUG; E1A PROTEIN; ETV4 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; BARRETT ESOPHAGUS; CANCER CELL; CANCER STAGING; CELL FUNCTION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; CELL MOTION; ESOPHAGUS TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOVIRUS E1A PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 1; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS;

EID: 78649776481     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-313     Document Type: Article

References (42)

1. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 2003, 17:655-664. 10.1046/j.1365-2036.2003.01520.x, 12641514.
2. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006, 13:12-30. 10.1245/ASO.2005.12.025, 16378161.
3. Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, Toyota T, Shimosegawa T. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001, 49:330-334. 10.1136/gut.49.3.330, 1728422, 11511552.
4. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
5. Adams R, Morgan M, Mukherjee S, Brewster A, Maughan T, Morrey D, Havard T, Lewis W, Clark G, Roberts S, Vachtsevanos L, Leong J, Hardwick R, Carey D, Crosby T. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol 2007, 33:307-313. 10.1016/j.ejso.2006.10.026, 17123775.
6. Wang VS, Hornick JL, Sepulveda JA, Mauer R, Poneros JM. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc 2009, 69:777-783. 10.1016/j.gie.2008.05.013, 19136106.
7. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004, 53:1070-1074. 10.1136/gut.2003.028076, 1774141, 15247170.
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, . MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20. 10.1056/NEJMoa055531, 16822992, MAGIC Trial Participants.
9. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994, 5:609-616.
10. Mackay HJ, McInnes A, Paul J, Raby N, Lofts FJ, McDonald AC, Soukop M, Fullarton GM, Harris AL, Garcia-Vargas J, Evans TR. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Ann Oncol 2001, 12:1407-1410. 10.1023/A:1012552823543, 11762812.
11. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol 2002, 13:1568-1575. 10.1093/annonc/mdf273, 12377644.
12. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001, 2:827-837. 10.1038/35099076, 11715049.
13. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003, 303:11-34. 10.1016/S0378-1119(02)01156-3, 12559563.
14. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, Verreman K. The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 2006, 1766:79-87.
15. Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007, 21:1882-1894. 10.1101/gad.1561707, 1935027, 17652178.
16. Boros J, O'Donnell A, Donaldson IJ, Kasza A, Zeef L, Sharrocks AD. Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members. Nucleic Acids Res 2009, 37:7368-7380. 10.1093/nar/gkp804, 2794171, 19789270.
17. Livet J, Sigrist M, Stroebel S, De Paola V, Price SR, Henderson CE, Jessell TM, Arber S. ETS gene Pea3 controls the central position and terminal arborization of specific motor neuron pools. Neuron 2002, 35:877-892. 10.1016/S0896-6273(02)00863-2, 12372283.
18. Kurpios NA, Sabolic NA, Shepherd TG, Fidalgo GM, Hassell JA. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 2003, 8:177-190. 10.1023/A:1025948823955, 14635793.
19. Kurpios NA, MacNeil L, Shepherd TG, Gludish DW, Giacomelli AO, Hassell JA. The Pea3 Ets transcription factor regulates differentiation of multipotent progenitor cells during mammary gland development. Dev Biol 2009, 325:106-121. 10.1016/j.ydbio.2008.09.033, 18977342.
20. Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci 2004, 95:626-633. 10.1111/j.1349-7006.2004.tb03320.x, 15298723.
21. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007, 21:1835-1846. 10.1210/me.2006-0480, 17505060.
22. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599. 10.1038/nature06024, 17671502.
23. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003, 200:568-576. 10.1002/path.1387, 12898592.
24. Yamamoto H, Horiuchi S, Adachi Y, Taniguchi H, Nosho K, Min Y, Imai K. Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. Carcinogenesis 2004, 25:325-332. 10.1093/carcin/bgh011, 14604892.
25. Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res 2007, 5:413-421. 10.1158/1541-7786.MCR-07-0019, 17475671.
26. Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S, Fujinaga K. A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 1996, 12:221-227.
27. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998, 185(3):256-261. 10.1002/(SICI)1096-9896(199807)185:3<256::AID-PATH115>3.0.CO;2-A, 9771478.
28. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001, 84:276-282. 10.1054/bjoc.2000.1568, 2363710, 11161388.
29. Xu H, Tanimoto A, Murata Y, Kimura S, Wang KY, Sasaguri Y. Difference in responsiveness of human esophageal squamous cell carcinoma lines to epidermal growth factor for MMP-7 expression. Int J Oncol 2003, 23:469-76.
30. O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA. The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 1996, 13:1323-1333.
31. O'Hagan RC, Hassell JA. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase. Oncogene 1998, 16:301-310.
32. Guo B, Sharrocks AD. Extracellular signal-regulated kinase mitogen-activated protein kinase signaling initiates a dynamic interplay between sumoylation and ubiquitination to regulate the activity of the transcriptional activator PEA3. Mol Cell Biol 2009, 29:3204-3218. 10.1128/MCB.01128-08, 2682013, 19307308.
33. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K. Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer 2000, 89:1670-6. 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J, 11042559.
34. Li X, Lu JY, Zhao LQ, Wang XQ, Liu GL, Liu Z, Zhou CN, Wu M, Liu ZH. Overexpression of ETS2 in human esophageal squamous cell carcinoma. World J Gastroenterol 2003, 9:205-8.
35. Chen AG, Yu ZC, Yu XF, Cao WF, Ding F, Liu ZH. Overexpression of Ets-like protein 1 in human esophageal squamous cell carcinoma. World J Gastroenterol 2006, 12:7859-63.
36. Guo B, Sallis RE, Greenall A, Petit MM, Jansen E, Young L, Van de Ven WJ, Sharrocks AD. The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3. Mol Cell Biol 2006, 26:4529-4538. 10.1128/MCB.01667-05, 1489114, 16738319.
37. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 2004, 279:20794-20806. 10.1074/jbc.M311131200, 14990565.
38. Hua D, Chen B, Bai M, Yu H, Wu X, Jin W. PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells. Acta Biochim Biophys Sin 2009, 41:63-68. 10.1093/abbs/gmn007, 19129951.
39. Jiang J, Wei Y, Liu D, Zhou J, Shen J, Chen X, Zhang S, Kong X, Gu J. E1AF promotes breast cancer cell cycle progression via upregulation of Cyclin D3 transcription. Biochem Biophys Res Commun 2007, 358:53-58. 10.1016/j.bbrc.2007.04.043, 17467662.
40. Funaoka K, Shindoh M, Yoshida K, Hanzawa M, Hida K, Nishikata S, Totsuka Y, Fujinaga K. Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. Biochem Biophys Res Commun 1997, 236:79-82. 10.1006/bbrc.1997.6909, 9223430.
41. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290. 10.1038/sj.onc.1210421, 17496922.
42. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 1996, 271:23907-23913. 10.1074/jbc.271.39.23907, 8798622.